Looney WJ, Narita M, Mühlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis. 2009;9(5):312–23. https://doi.org/10.1016/S1473-3099(09)70083-0.
Article
CAS
PubMed
Google Scholar
Micozzi A, Venditti M, Monaco M, Friedrich A, Taglietti F, Santilli S, et al. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2000;31(3):705–11. https://doi.org/10.1086/314043.
Article
CAS
Google Scholar
Al-Anazi KA, Al-Jasser AM. Infections caused by Stenotrophomonas maltophilia in recipients of hematopoietic stem cell transplantation. Front Oncol. 2014;4:232.
PubMed
PubMed Central
Google Scholar
Cho SY, Lee DG, Choi SM, Park C, Chun HS, Park YJ, et al. Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations. BMC Infect Dis. 2015;15(1):69. https://doi.org/10.1186/s12879-015-0801-7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Baumrin E, Piette EW, Micheletti RG. Stenotrophomonas maltophilia: an emerging multidrug-resistant opportunistic pathogen in the immunocompromised host. BMJ Case Rep. 2017;2017:bcr2017221053.
Guerci P, Bellut H, Mokhtari M, Gaudefroy J, Mongardon N, Charpentier C, et al. Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study. Crit Care (London, England). 2019;23(1):371.
Article
Google Scholar
Metan G, Uzun O. Impact of initial antimicrobial therapy in patients with bloodstream infections caused by Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2005;49(9):3980–1. https://doi.org/10.1128/AAC.49.9.3980-3981.2005.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sumida K, Chong Y, Miyake N, Akahoshi T, Yasuda M, Shimono N, et al. Risk factors associated with Stenotrophomonas maltophilia bacteremia: a matched case-control study. PLoS One. 2015;10(7):e0133731. https://doi.org/10.1371/journal.pone.0133731.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kim SH, Cho SY, Kang CI, Seok H, Huh K, Ha YE, et al. Clinical predictors of Stenotrophomonas maltophilia bacteremia in adult patients with hematologic malignancy. Ann Hematol. 2018;97(2):343–50. https://doi.org/10.1007/s00277-017-3178-4.
Article
PubMed
Google Scholar
Mori M, Tsunemine H, Imada K, Ito K, Kodaka T, Takahashi T. Life-threatening hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in the treatment of hematologic diseases. Ann Hematol. 2014;93(6):901–11. https://doi.org/10.1007/s00277-014-2028-x.
Article
CAS
PubMed
Google Scholar
Kim EJ, Kim YC, Ahn JY, Jeong SJ, Ku NS, Choi JY, et al. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone-resistant strains. BMC Infect Dis. 2019;19(1):754. https://doi.org/10.1186/s12879-019-4394-4.
Article
CAS
PubMed
PubMed Central
Google Scholar
Imoto W, Yamada K, Yamairi K, Shibata W, Namikawa H, Yukawa S, et al. Clinical Characteristics of Rapidly Progressive Fatal Hemorrhagic Pneumonia Caused by Stenotrophomonas maltophilia. Intern Med (Tokyo, Japan). 2020;59(2):193–8.
Article
CAS
Google Scholar
Araoka H, Fujii T, Izutsu K, Kimura M, Nishida A, Ishiwata K, et al. Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancy. Transplant infectious disease : an official journal of the Transplantation Society. 2012;14(4):355–63. https://doi.org/10.1111/j.1399-3062.2011.00710.x.
Article
CAS
Google Scholar
Tada K, Kurosawa S, Hiramoto N, Okinaka K, Ueno N, Asakura Y, et al. Stenotrophomonas maltophilia infection in hematopoietic SCT recipients: high mortality due to pulmonary hemorrhage. Bone Marrow Transplant. 2013;48(1):74–9. https://doi.org/10.1038/bmt.2012.87.
Article
CAS
PubMed
Google Scholar
Gutierrez C, Pravinkumar E, Balachandran D, Schneider V. Fatal hemorrhagic pneumonia: Don't forget Stenotrophomonas maltophilia. Respiratory medicine case reports. 2016;19:12–4. https://doi.org/10.1016/j.rmcr.2016.06.003.
Article
PubMed
PubMed Central
Google Scholar
Katayama O, Kitagawa T, Onaka T, Yonezawa A. Rapidly progressive hemorrhagic pneumonia caused by Stenotrophomonas maltophilia occurring early after bone marrow transplantation in a patient with myelodysplastic syndrome. Rinsho ketsueki. 2017;58(4):323–5. https://doi.org/10.11406/rinketsu.58.323.
Article
PubMed
Google Scholar
Kim SH, Cha MK, Kang CI, Ko JH, Huh K, Cho SY, et al. Pathogenic significance of hemorrhagic pneumonia in hematologic malignancy patients with Stenotrophomonas maltophilia bacteremia: clinical and microbiological analysis. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2019;38(2):285–95. https://doi.org/10.1007/s10096-018-3425-1.
Article
CAS
Google Scholar
Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–32. https://doi.org/10.1016/j.ajic.2008.03.002.
Article
Google Scholar
Humphries RM, Ambler J, Mitchell SL, Castanheira M, Dingle T, Hindler JA, et al. CLSI Methods Development and Standardization Working Group Best Practices for Evaluation of Antimicrobial Susceptibility Tests. J Clin Microbiol. 2018;56(4):e01934-17.
Guan X, He L, Hu B, Hu J, Huang X, Lai G, et al. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2016;22 Suppl 1: S15–25.
Bao H, Qiao Y, Liu D, Chen J, Wu X, Hu X, et al. The clinical impact of Stenotrophomonas maltophilia bacteremia on the 30-day mortality rate in patients with hematologic disorders: a single-institution experience. Infection. 2020;48(2):205-12.
Penagos SC, Giraldo N, Vallejo C, McEwen O, Hidron A. First report of survival in two patients with hematologic malignancy and Stenotrophomonas maltophilia hemorrhagic pneumonia treated with trimethoprim-sulfamethoxazole-based combination antibiotic therapy. J Infect Chemother. 2020;26(4):397–9. https://doi.org/10.1016/j.jiac.2019.12.003.
Koivula I, Hämäläinen S, Jantunen E, Pulkki K, Kuittinen T, Nousiainen T, et al. Elevated procalcitonin predicts gram-negative sepsis in haematological patients with febrile neutropenia. Scand J Infect Dis. 2011;43(6–7):471–8. https://doi.org/10.3109/00365548.2011.554855.
von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C, et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis. 2004;23(7):539–44.
Juutilainen A, Hämäläinen S, Pulkki K, Kuittinen T, Nousiainen T, Jantunen E, et al. Biomarkers for bacteremia and severe sepsis in hematological patients with neutropenic fever: multivariate logistic regression analysis and factor analysis. Leukemia & lymphoma. 2011;52(12):2349–55.
Yang M, Choi SJ, Lee J, Lee DG, Kim YJ, Park YJ, et al. Serum procalcitonin as an independent diagnostic markers of bacteremia in febrile patients with hematologic malignancies. PLoS One. 2019;14(12):e0225765. https://doi.org/10.1371/journal.pone.0225765.
Yunus I, Fasih A, Wang Y. The use of procalcitonin in the determination of severity of sepsis, patient outcomes and infection characteristics. PLoS One. 2018;13(11):e0206527. https://doi.org/10.1371/journal.pone.0206527.
Massaro KS, Costa SF, Leone C, Chamone DA. Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis. 2007;7(1):137. https://doi.org/10.1186/1471-2334-7-137.
Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389–99. https://doi.org/10.1080/10408363.2020.1770685.
Tekçe YT, Erbay A, Cabadak H, Sen S. Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections. J Chemother. 2012;24(3):150–4. https://doi.org/10.1179/1120009X12Z.00000000022.
Pfaller MA, Huband MD, Streit JM, Flamm RK, Sader HS. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016). Int J Antimicrob Agents. 2018;51(6):848–53. https://doi.org/10.1016/j.ijantimicag.2018.01.006.
Zhao J, Liu Y, Liu Y, Wang D, Ni W, Wang R, et al. Frequency and genetic determinants of Tigecycline resistance in clinically isolated Stenotrophomonas maltophilia in Beijing, China. Front Microbiol. 2018;9:549. https://doi.org/10.3389/fmicb.2018.00549.
Windhorst S, Frank E, Georgieva DN, Genov N, Buck F, Borowski P, et al. The major extracellular protease of the nosocomial pathogen Stenotrophomonas maltophilia: characterization of the protein and molecular cloning of the gene. J Biol Chem. 2002;277(13):11042–9. https://doi.org/10.1074/jbc.M109525200.
Cui N, Cai H, Li Z, Lu Y, Wang G, Lu A. Tigecycline-induced coagulopathy: a literature review. Int J Clin Pharm. 2019;41(6):1408–13. https://doi.org/10.1007/s11096-019-00912-5.
Blanco P, Corona F, Martinez JL. Mechanisms and phenotypic consequences of acquisition of tigecycline resistance by Stenotrophomonas maltophilia. J Antimicrob Chemother. 2019;74(11):3221–30. https://doi.org/10.1093/jac/dkz326.